Page last updated: 2024-12-07
rx-ra 69
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
RX-RA 69: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 132466 |
| SCHEMBL ID | 10659585 |
| MeSH ID | M0108829 |
Synonyms (11)
| Synonym |
|---|
| rx-ra 69 |
| 8-benzylthio-4-morpholino-2-piperazino-pyrimido(5,4-d)pyrimidine |
| pyrimido(5,4-d)pyrimidine, 4-(4-morpholinyl)-8-((phenylmethyl)thio)-2-(1-piperazinyl)- |
| 8-benzylthio-4-morpholino-2-piperazinylpyrimido(5,4-d)pyrimidine |
| 4-(4-morpholinyl)-8-((phenylmethyl)thio)-2-(1-piperazinyl)pyrimido(5,4-d)pyrimidine |
| 77749-49-6 |
| 4-(8-benzylsulfanyl-2-piperazin-1-ylpyrimido[5,4-d]pyrimidin-4-yl)morpholine |
| 8-benzylthio-4-morpholino-2-piperazino-pyrimido-[5,4-d]-pyrimidine |
| LUGKHBNNJJSVLE-UHFFFAOYSA-N |
| DTXSID40228367 |
| SCHEMBL10659585 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The same dosage is able to prevent the drop in platelet count induced by injecting a large number of tumor cells into mice." | ( Antimetastatic action of RX-RA 69, a new potent PDE-inhibitor in the Lewis lung carcinoma of the mouse. Haarmann, W; Lichtner, R, 1982) | 0.57 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||